

2020 PNS Virtual Event

27 JUNE – 30 JUNE, 2020



1113. Rare mutational variant (Ile93Val) of hereditary amyloidosis with severe dysautonomia treated with inotersen (ASO).

A. Rodríguez, P. Landriscina, R. Pedelhez, L. Mosqueras
INEBA. Buenos Aires. Argentina



Introduction

- Hereditary transthyretin amyloidosis (h-ATTR) is a disease caused by the mutation of the TTR gene, generating deposits of the mutated protein in different organs, the systems affected are related to the type of mutation found.
- The Val50met variant (VAL30met) is the most frequent mutation and The early onset presentation is characterized by peripheral neuropathy. It is a rare, progressive and fatal disease, with treatment options today.

1113. Rare mutational variant (Ile93Val) of heredity amyloidosis with severe dysautonomia treated with inotersen (ASO).
A. Rodríguez, P. Landriscina, R. Pedelhez, L. Mosqueras
INEBA. Buenos Aires. Argentina


Objetives

- To present a case report with a rare mutation in treatment with antisense-Oligonucleotide(ASO), inotersen.

1113. Rare mutational variant (Ile93Val) of hereditary amyloidosis with severe dysautonomia treated with inotersen (ASO).
A. Rodríguez, P. Landriscina, R. Pedelhez, L. Mosqueras
INEBA. Buenos Aires. Argentina

Methods and Materials

- 50-year-old male, with a history of gastrointestinal disorders (GI), weight loss, erectile dysfunction, syncopes and paraesthesia in the territory of both medium nerves and lower limbs of 5 years of evolution.
- Family history: father and paternal uncle with GI disorders.
- On neurological examination as positive signs: distal lower limb hypoaesthesia, bilateral positive Tinel sign.
- Conduction velocity electromyogram (EMG), Quantitative sensory testing (QST), evaluation of the autonomic nervous system (SNA), skin and salivary gland biopsy and next generation sequencing for TTR gene are requested.



1113. Rare mutational variant (Ile93Val) of hereditary amyloidosis with severe dysautonomia treated with inotersen (ASO).
A. Rodríguez, P. Landriscina, R. Pedelhez, L. Mosqueras
INEBA. Buenos Aires. Argentina

Results

- **EMG**: bilateral carpal tunnel syndrome, **QST**: dysfunction of type C unmyelinated fibers, alteration in the evaluation of ANS. **Echocardiography studies (strain)** showed pattern compatible with amyloid deposits. **Genetic analysis** demonstrated the presence of **Ile93val mutation**, a rare genetic variant in the TTR gene. Due to the severe autonomic involvement and infrequent mutation of the patient, it was decided to start treatment with **inotersen 284 mg.** weekly subcutaneous, in current follow-up with good tolerance to it.

1113. Rare mutational variant (Ile93Val) of heredity amyloidosis with severe dysautonomia treated with inotersen (ASO).
A. Rodríguez, P. Landriscina, R. Pedelhez, L. Mosqueras
INEBA. Buenos Aires. Argentina

Results



Echocardiography studies (strain) showed pattern compatible with amyloid deposits

Resultado

Diagnóstico: Amiloidosis asociada al gen TTR

Gen	Posición	Variante	Consecuencia	Copias
TTR	chr18:29.175.159	A > G	p.Ile93Val ENST00000237014	Heterocigosis (1 copia)


Genetic analysis demonstrated the presence of Ile93val mutation





Biopsy of salivary glands with Congo red was negative.

1113. Rare mutational variant (Ile93Val) of heredity amyloidosis with severe dysautonomia treated with inotersen (ASO).
A. Rodríguez, P. Landriscina, R. Pedelhez, L. Mosqueras
INEBA. Buenos Aires. Argentina

Results



Biweekly platelet count throughout inotersen treatment.



Compas-31 and Norfolk scale, before and 10 months after starting treatment.

1113. Rare mutational variant (Ile93Val) of heredity amyloidosis with severe dysautonomia treated with inotersen (ASO).
A. Rodríguez, P. Landriscina, R. Pedelhez, L. Mosqueras
 INEBA. Buenos Aires. Argentina

Conclusions

- This rare mutation, **Ile93Val**, is reported for the **first time in Argentina**, existing only reports of it in Taiwan and Bangladesh. **Early onset with dysautonomia that precedes peripheral neurological involvement** seems to be characteristic of this variant. Subsequent studies in **patient follow-up** may determine the **impact of inotersen** treatment on this form of presentation.

1113. Rare mutational variant (Ile93Val) of hereditary amyloidosis with severe dysautonomia treated with inotersen (ASO).
A. Rodríguez, P. Landriscina, R. Pedelhez, L. Mosqueras
INEBA. Buenos Aires. Argentina

Many Thanks.



Dr. Rodríguez Alejandro Martín
alejrodrig@intramed.net

1113. Rare mutational variant (Ile93Val) of hereditary amyloidosis with severe dysautonomia treated with inotersen (ASO).
A. Rodríguez, P. Landriscina, R. Pedelhez, L. Mosqueras
INEBA. Buenos Aires. Argentina

2020 PNS Virtual Event

